Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04282551
Other study ID # NL70126.081.19
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 24, 2020
Est. completion date November 2022

Study information

Verified date October 2021
Source Wageningen University and Research
Contact Clara Belzer, PhD
Phone 0031317-483742
Email clara.belzer@wur.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the present randomised double blind controlled study, the investigators will study the effects of oligosaccharides vs a placebo on the change in stool consistency and stool frequency in children with functional constipation.


Description:

Functional constipation (FC) in children is a common gastrointestinal (GI) disorder with a worldwide prevalence ranging from 0.7% to 29.6%. Complaints include infrequent bowel movement, painful defecation due to hard and/or large stools, fecal incontinence, and abdominal pain. Although the condition is rarely life-threatening, it strongly impairs quality of life. Oligosaccharides have been shown to relieve constipation symptoms in young adults and elderly. However, sufficient evidence is lacking linking oligosaccharides intake to improve symptoms in children with FC. The investigators hypothesize that oligosaccharides might be able to relieve symptoms of constipation in young children as well, among which softening stools.


Recruitment information / eligibility

Status Recruiting
Enrollment 198
Est. completion date November 2022
Est. primary completion date November 2022
Accepts healthy volunteers No
Gender All
Age group 1 Year to 3 Years
Eligibility In order to be eligible to participate in this study, a subject must meet all of the following criteria, as considered by a medical doctor: - Written informed consent - Aged 1-3 years - Children that meet the Rome IV criteria for functional constipation Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Children who suffer from any other GI complaints than functional constipation, known structural GI abnormalities, or previous GI surgery - Any condition that would make it unsafe for the child to participate. - Children with clinically significant cardiac, vascular, liver, pulmonary, psychiatric disorders, severe renal insufficiency, human immunodeficiency virus, acquired immunodeficiency syndrome, hepatitis B or C or known abnormalities of haematology, urinalysis, or blood biochemistry - Children who are allergic to cow's milk or fish - Use of antibiotics or other medicines or food supplements, and breast milk-feeding, 4 weeks prior to the study, except for the allowed escape medication - Children that participate in another clinical trial

Study Design


Related Conditions & MeSH terms


Intervention

Other:
dietary intervention with oligosaccharides
intervention with oligosaccharide 1 or 2, or placebo, given once a day

Locations

Country Name City State
Netherlands Emma Children's Hospital, UMC Amsterdam Amsterdam Noord-Holland

Sponsors (4)

Lead Sponsor Collaborator
Wageningen University and Research Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), FrieslandCampina, Amersfoort, The Netherlands, Sensus (Royal Cosun), the Netherlands.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Stool consistency Change in stool consistency measured by the a stool questionnaire; 5 points stool scale from 1 hard to 5 watery (modified Bristol Stool Form Scale) Stool consistency will be measured at different time points during a study period of 13 weeks.
Secondary Stool frequency in number of cases (%) Stool frequency - number of times a child has stools a day as reported in a diary. These outcome measures will be measured at different time point during a study period of 13 weeks.
Secondary Stool consistency in number of cases (%) Stool consistency - % of stools in a certain stool scale score as measured via a 5 point stool scale These outcome measures will be measured at different time point during a study period of 13 weeks.
See also
  Status Clinical Trial Phase
Completed NCT04506801 - The Effect of Probiotics on Functional Constipation in the Elderly N/A
Completed NCT04620161 - A Proof of Concept Study of Pradigastat in Patients With Functional Constipation Phase 2
Active, not recruiting NCT02361749 - Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation Phase 4
Completed NCT03054805 - The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation Phase 4
Not yet recruiting NCT01913665 - The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation N/A
Completed NCT01622972 - Mode of Action of Moviprep Phase 4
Completed NCT01348152 - Effect of TU-100 in Patients With Functional Constipation Phase 2
Completed NCT01212146 - Probiotic-enriched Artichoke in Functional Constipation N/A
Completed NCT04231162 - Effect of an 8-week Bifidobacterium Lactis HN019 Supplementation on Functional Constipation N/A
Not yet recruiting NCT03639142 - Dried Plums (Prunes) vs. Polyethylene Glycol 4000 for Treatment of Functional Constipation in Children Phase 3
Recruiting NCT04918329 - Functional Digestive Disorders Observatory
Completed NCT02592200 - Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women N/A
Completed NCT03707002 - Effect of scFOS on Increase in Stool Frequency in Constipated People N/A
Recruiting NCT06083311 - The Efficacy of a Probiotic for Functional Constipation (FC) N/A
Completed NCT04110145 - Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation Phase 2
Recruiting NCT06196073 - Visceral Osteopathy in Functional Constipation N/A
Completed NCT04026113 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Phase 3
Completed NCT02359396 - A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics Phase 1
Completed NCT01847950 - Effects of scFOS on Stool Frequency in People With Functionnal Constipation N/A
Recruiting NCT01274793 - Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy Phase 1